Keywords: Roche, Obinutuzumab, Leukemia, CLL, Ph III, GA101, MabThera, Rituxan

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

Article | 04 February 2013

Print This

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in